South Korean Health Ministry Mulls European-like Reference Pricing
This article was originally published in PharmAsia News
Executive Summary
South Korea’s Ministry of Health and Welfare considers launching a reference-pricing system similar to many European countries.
You may also be interested in...
Germany’s Pricing Revolution: Why The World Should Be Watching
Germany’s new early-benefit assessment system for all new drugs launched since Jan. 1, 2011, radically changes the status of Europe’s largest market. It was once a bastion of free (and thus relatively high) pricing, which firms used to signal their drugs’ value to other markets. Now, prices of new drugs will be negotiated between sponsors and the country’s association of statutory sick funds, on the basis of an added-benefit score determined by the G-BA, or Federal Joint Committee. Since those net prices will be made public, and many other countries reference German prices, there’s a real risk of a downward price spiral across Europe.
Korea's Health Ministry Flip-Flops Again On OTC Drug Position; Now Seeks Expanded Consumer Access
SEOUL - Just a few days after South Korea's Ministry of Health and Welfare announced it would not allow sales of OTC drugs at supermarkets and convenience stores, the ministry is reversing its position, saying it will now push for a revision of Korea's drug law to allow sales of OTC products in the stores
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.